{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:23:42Z","timestamp":1773278622243,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3447,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1038\/mt.sj.6300120","type":"journal-article","created":{"date-parts":[[2007,3,20]],"date-time":"2007-03-20T16:13:06Z","timestamp":1174407186000},"page":"1016-1023","source":"Crossref","is-referenced-by-count":111,"title":["Phase I Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy Combined with IMRT for Prostate Cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"Svend O","family":"Freytag","sequence":"first","affiliation":[]},{"given":"Benjamin","family":"Movsas","sequence":"additional","affiliation":[]},{"given":"Ibrahim","family":"Aref","sequence":"additional","affiliation":[]},{"given":"Hans","family":"Stricker","sequence":"additional","affiliation":[]},{"given":"James","family":"Peabody","sequence":"additional","affiliation":[]},{"given":"Jan","family":"Pegg","sequence":"additional","affiliation":[]},{"given":"Yingshu","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Kenneth N","family":"Barton","sequence":"additional","affiliation":[]},{"given":"Stephen L","family":"Brown","sequence":"additional","affiliation":[]},{"given":"Mei","family":"Lu","sequence":"additional","affiliation":[]},{"given":"Adnan","family":"Savera","sequence":"additional","affiliation":[]},{"given":"Jae Ho","family":"Kim","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1038\/mt.sj.6300120_bib1","series-title":"Cancer facts and figures 2005","author":"American Cancer Society","year":"2005"},{"key":"10.1038\/mt.sj.6300120_bib2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1038\/mt.sj.6300120_bib3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jama.281.17.1598","article-title":"Radiation therapy for clinically localized prostate cancer","volume":"281","author":"Shipley","year":"1999","journal-title":"JAMA"},{"key":"10.1038\/mt.sj.6300120_bib4","first-page":"6053","article-title":"Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene","volume":"54","author":"Kim","year":"1994","journal-title":"Cancer Res"},{"key":"10.1038\/mt.sj.6300120_bib5","first-page":"53","article-title":"Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene","volume":"2","author":"Khil","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.sj.6300120_bib6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/hum.1998.9.9-1323","article-title":"A novel three-pronged approach to selectively kill cancer cells: concomitant viral, double suicide gene, and radiotherapy","volume":"9","author":"Freytag","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.sj.6300120_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/10430340050016166","article-title":"Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization","volume":"11","author":"Rogulski","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.sj.6300120_bib8","first-page":"1193","article-title":"In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy","volume":"60","author":"Rogulski","year":"2000","journal-title":"Cancer Res"},{"key":"10.1038\/mt.sj.6300120_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0360-3016(02)03005-5","article-title":"Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model","volume":"54","author":"Freytag","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib10","first-page":"4968","article-title":"Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer","volume":"62","author":"Freytag","year":"2002","journal-title":"Cancer Res"},{"key":"10.1038\/mt.sj.6300120_bib11","first-page":"7497","article-title":"Phase I study of replication-competent adenovirus-mediated double suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly-diagnosed, intermediate- to high-risk prostate cancer","volume":"63","author":"Freytag","year":"2003","journal-title":"Cancer Res"},{"key":"10.1038\/mt.sj.6300120_bib12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.mt.6300068","article-title":"Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.sj.6300120_bib13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/10430349950018229","article-title":"In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial","volume":"10","author":"Herman","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.sj.6300120_bib14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0360-3016(01)01692-3","article-title":"Phase I\/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer\u2014a preliminary report","volume":"51","author":"Teh","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib15","first-page":"7464","article-title":"A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res"},{"key":"10.1038\/mt.sj.6300120_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/10430340360535788","article-title":"Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer","volume":"14","author":"Kubo","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.sj.6300120_bib17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.ijrobp.2003.09.083","article-title":"Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data","volume":"58","author":"Teh","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","article-title":"A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer","volume":"14","author":"Small","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mt.sj.6300120_bib19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ymthe.2005.10.005","article-title":"Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and the ADP gene demonstrates greater efficacy without increased toxicity","volume":"13","author":"Barton","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mt.sj.6300120_bib20","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/JVI.70.4.2296-2306.1996","article-title":"The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells","volume":"70","author":"Tollefson","year":"1996","journal-title":"J Virol"},{"key":"10.1038\/mt.sj.6300120_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1006\/viro.1996.0295","article-title":"The E3-11.6 kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants","volume":"220","author":"Tollefson","year":"1996","journal-title":"Virology"},{"key":"10.1038\/mt.sj.6300120_bib22","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/JVI.74.13.6147-6155.2000","article-title":"Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein","volume":"74","author":"Doronin","year":"2000","journal-title":"J Virol"},{"key":"10.1038\/mt.sj.6300120_bib23","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1128\/JVI.75.7.3314-3324.2001","article-title":"Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy","volume":"75","author":"Doronin","year":"2001","journal-title":"J Virol"},{"key":"10.1038\/mt.sj.6300120_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.cgt.7700555","article-title":"Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein","volume":"10","author":"Toth","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.sj.6300120_bib25","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0360-3016(02)02977-2","article-title":"Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial","volume":"54","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib27","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-5347(05)65855-7","article-title":"High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer","volume":"166","author":"Zelefsky","year":"2001","journal-title":"J Urol"},{"key":"10.1038\/mt.sj.6300120_bib28","first-page":"1035","article-title":"Consensus statement: guidelines for PSA following radiation therapy","volume":"37","author":"Cox","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2005.05.053","article-title":"Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer","volume":"63","author":"Buyounouski","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib30","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2006.06.017","article-title":"Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer specific survival: an analysis of radiation therapy oncology group protocol 92-02","volume":"66","author":"Valicenti","year":"2006","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-5347(01)64518-X","article-title":"Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate","volume":"158","author":"Fleshner","year":"1997","journal-title":"J Urol"},{"key":"10.1038\/mt.sj.6300120_bib32","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0022-5347(01)64159-4","article-title":"Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer","volume":"158","author":"Epstein","year":"1997","journal-title":"J Urol"},{"key":"10.1038\/mt.sj.6300120_bib33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0090-4295(97)00306-3","article-title":"The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer","volume":"50","author":"Norberg","year":"1997","journal-title":"Urology"},{"key":"10.1038\/mt.sj.6300120_bib34","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/00005392-199805000-00052","article-title":"Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer","volume":"159","author":"Svetec","year":"1998","journal-title":"J Urol"},{"key":"10.1038\/mt.sj.6300120_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0022-5347(01)65322-9","article-title":"Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate","volume":"157","author":"Eskew","year":"1997","journal-title":"J Urol"},{"key":"10.1038\/mt.sj.6300120_bib36","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0090-4295(99)80054-5","article-title":"Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients","volume":"45","author":"Crook","year":"1995","journal-title":"Urology"},{"key":"10.1038\/mt.sj.6300120_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<81::AID-CNCR12>3.0.CO;2-2","article-title":"Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma","volume":"79","author":"Crook","year":"1997","journal-title":"Cancer"},{"key":"10.1038\/mt.sj.6300120_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<328::AID-CNCR16>3.0.CO;2-2","article-title":"Radiotherapy for localized prostate carcinoma: the correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen","volume":"79","author":"Crook","year":"1997","journal-title":"Cancer"},{"key":"10.1038\/mt.sj.6300120_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0360-3016(00)00637-4","article-title":"Postradiotherapy prostate biopsies: what do they really mean? results for 498 patients","volume":"48","author":"Crook","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib40","first-page":"95","article-title":"Local control of prostate cancer with radiotherapy. Frequency and prognostic significance of positive results of postirradiation prostate biopsy","volume":"7","author":"Scardino","year":"1988","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1038\/mt.sj.6300120_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0360-3016(92)91053-P","article-title":"The significance of post-irradiation prostate biopsy with long-term follow-up","volume":"24","author":"Kuban","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0360-3016(92)91052-O","article-title":"The clinical significance of a positive post-irradiation prostatic biopsy without metastases","volume":"24","author":"Prestidge","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.sj.6300120_bib43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00000478-199601000-00010","article-title":"Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study","volume":"20","author":"Vaillancourt","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/mt.sj.6300120_bib44","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for coxsackie B viruses and adenovirus 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1038\/mt.sj.6300120_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"10.1038\/mt.sj.6300120_bib46","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1089\/hum.1998.9.16-2363","article-title":"The presence of human coxsackie and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures","volume":"9","author":"Hemmi","year":"1998","journal-title":"Gene Ther"},{"key":"10.1038\/mt.sj.6300120_bib47","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1099\/vir.0.80806-0","article-title":"Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie\u2013adenovirus receptor and alpha v beta 5 integrin expression","volume":"86","author":"Richardson","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1038\/mt.sj.6300120_bib48","first-page":"325","article-title":"Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy","volume":"59","author":"Li","year":"1999","journal-title":"Cancer Res"},{"key":"10.1038\/mt.sj.6300120_bib49","first-page":"5031","article-title":"The dual impact of coxsackie and adenovirus receptor expression in human prostate cancer gene therapy","volume":"60","author":"Okegawa","year":"2000","journal-title":"Cancer Res"},{"key":"10.1038\/mt.sj.6300120_bib50","first-page":"3812","article-title":"Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy","volume":"62","author":"Rauen","year":"2002","journal-title":"Cancer Res"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616316549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616316549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T01:11:19Z","timestamp":1587431479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616316549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S1525001616316549"],"URL":"https:\/\/doi.org\/10.1038\/mt.sj.6300120","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}